期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 439, 期 C, 页码 369-378出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2016.09.026
关键词
Neohesperidin; Osteoclasts; Osteoporosis; Inhibition
资金
- Co-innovation Centre for Bio-Medicine, Guangxi Colleges and University Key Laboratory of Regenerative Medicine and Innovation Team of Tissue Repair and Reconstruction
- Department of Orthopaedic Surgery of the First Affiliated Hospital of Guangxi Medical University
- School of Pathology and Laboratory Medicine of the University of Western Australia [NHMRC1107828]
- Nature Science Foundation of Guangxi [2015GXNSFDA139019]
- Guangxi Scientific Research and Technology Development project [GKG13349003]
- China Postdoctoral Science Foundation [2015M572421]
- Shanghai Pujiang Program [14PJ1406200]
Excessive bone resorption by osteoclasts plays an important role in osteoporosis. Bone loss occurs in ovariectomised (OVX) mice in a similar manner to that in humans, so this model is suitable for evaluating potential new therapies for osteoporosis. Neohesperidin (NE) is a flavonoid compound isolated from citrus fruits. Its role in bone metabolism is unknown. In this study we found that neohesperidin inhibits osteoclast differentiation, bone resorption and the expression of osteoclast marker genes, tartrate resistant acid phosphatase and cathepsin K. In addition, neohesperidin inhibited receptor activator of NF-kappa B ligand (RANKL)-induced activation of NF-kappa B, and the degradation of inhibitor of kappa B-alpha (I kappa B alpha). Furthermore, neohesperidin inhibited RANKL induction of nuclear factor of activated T-cells (NFAT) and calcium oscillations. In vivo treatment of ovariectomised mice with neohesperidin protected against bone loss in mice. The results suggest neohesperidin has anti-osteoclastic effects in vitro and in vivo and possesses therapeutic potential as a natural anti-catabolic treatment in osteoporosis. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据